Our country's innovative drugs had foreign licensing deals worth nearly 66 billion US dollars in the first half of the year.

Today, the reporter learned from the Chinese Biopharmaceutical Quality Control Conference that the State Drug Administration has approved 56 new innovative drugs this year, 18 of which are biopharmaceutical products, including the first stem cell therapy product, the first hemophilia gene therapy product, and many of them are "globally first launched". The State Drug Administration stated that biopharmaceutical products represent the forefront of the contemporary biopharmaceutical technology revolution, providing new treatment possibilities for many major and rare diseases, and are the most rapidly developing and innovative areas in the pharmaceutical industry. In addition, China's advanced therapeutic drugs have surged significantly, with 2,400 products in the research pipeline; China has been elected as a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Committee for three consecutive times, implementing and transforming 71 ICH guidelines. Currently, innovative drugs developed globally can be simultaneously applied for and launched in China, with several innovative drugs achieving global "first launches" in China. According to incomplete statistics, the total amount of authorized external transactions for Chinese innovative drugs in the first half of 2025 was nearly 66 billion US dollars, exceeding the total amount of 51.9 billion US dollars in the whole year of 2024.